Plasma-derived biological medicines used to promote haemostasis

HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOOD

1981 • 1,659 citations

Immunomodulation of Autoimmune and Inflammatory Diseases with Intravenous Immune Globulin

2001 • 1,211 citations

Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc Receptor

2001 • 1,037 citations

The epidemiology of inhibitors in haemophilia A: a systematic review

2003 • 603 citations

ANTI-IDIOTYPIC SUPPRESSION OF AUTOANTIBODIES TO FACTOR VIII (ANTIHAEMOPHILIC FACTOR) BY HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN

1984 • 485 citations

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

2006 • 459 citations

Intravenous Administration of Human γ‐Globulin*

1962 • 389 citations

The Treatment of Bleeding in Acquired Haemophilia with Recombinant Factor VIIa: A Multicentre Study

1997 • 356 citations

Factors influencing the immunogenicity of therapeutic proteins

2005 • 323 citations

EFFECT OF INTRAVENOUS IMMUNOGLOBULIN IN IMMUNE THROMBOCYTOPENIA

1983 • 309 citations

Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin

2002 • 305 citations

The Effect of Activated Prothrombin-Complex Concentrate (FEIBA) on Joint and Muscle Bleeding in Patients with Hemophilia A and Antibodies to Factor VIII

1981 • 303 citations

Multicenter Retrospective Study on the Utilization of FEIBA in France in Patients with Factor VIII and Factor IX Inhibitors

1997 • 287 citations

Rapid method for the purification of bovine thrombin and the inhibition of the purified enzyme with phenylmethylsulfonyl fluoride

1971 • 281 citations

Immune Responses to Therapeutic Proteins in Humans - Clinical Significance, Assessment and Prediction

2002 • 253 citations

A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs

2007 • 247 citations

A model for the tissue factor pathway to thrombin. I. An empirical study.

1994 • 242 citations

Immunologic Impact and Clinical Outcomes After Surgical Exposure to Bovine Thrombin

2001 • 232 citations

Nanofiltration of plasma‐derived biopharmaceutical products

2003 • 206 citations

Clinical benefits and risk analysis of topical hemostats: a review

2005 • 206 citations

Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure

2002 • 197 citations

Guidelines on the Use of Intravenous Immune Globulin for Hematologic Conditions

2007 • 185 citations

Absorbable hemostatic agents

2006 • 185 citations

Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site

1995 • 181 citations

Committee for Proprietary Medicinal Products (CPMP)

2009 • 178 citations

A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin

1995 • 171 citations

Human Immune Response to Recombinant Human Proteins

2001 • 170 citations

A Phase 3, Randomized, Double-Blind Comparative Study of the Efficacy and Safety of Topical Recombinant Human Thrombin and Bovine Thrombin in Surgical Hemostasis

2007 • 170 citations

Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A

2007 • 168 citations

Treatment of acquired haemophilia with factor eight inhibitor bypassing activity

2004 • 164 citations

Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D))

1984 • 156 citations

Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rho(D) immune globulin intravenous administration for immune thrombocytopenic purpura

2005 • 155 citations

Immunogenicity of recombinant human proteins: causes and consequences

2004 • 153 citations

A study of liver biopsies and liver disease among hemophiliacs

1985 • 150 citations

Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rho(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients

2000 • 147 citations

Inhibitors in congenital coagulation disorders

2004 • 147 citations

Immunogenicity of therapeutic proteins

2003 • 145 citations

Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals.

1992 • 141 citations

The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1

1999 • 139 citations

Guidelines on the Use of Intravenous Immune Globulin for Neurologic Conditions

2007 • 135 citations

Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbα antibodies

2006 • 128 citations

Fibrin sealant: current and potential clinical applications.

1996 • 123 citations

Topical thrombin and acquired coagulation factor inhibitors: Clinical spectrum and laboratory diagnosis

1994 • 123 citations

Recombinant clotting factors

2008 • 104 citations

Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?

2005 • 102 citations

Pharmacokinetic analysis of plasma‐derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B

2002 • 100 citations

Enveloped Virus Inactivation by Caprylate: A Robust Alternative to Solvent-Detergent Treatment in Plasma Derived Intermediates

2002 • 98 citations

Pathogen inactivation technology: cleansing the blood supply

2005 • 94 citations

The use of human fibrin glue in the surgical operations.

2003 • 92 citations

Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma‐product exposed toddlers)

2007 • 90 citations

Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies

2005 • 89 citations

Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg)

1992 • 85 citations

Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients

1994 • 84 citations

Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response

2007 • 81 citations

Clinical use of Haemate(R) P in inherited von Willebrand's disease: a cohort study on 100 Italian patients

2007 • 79 citations

FEIBA^® safety profile in multiple modes of clinical and home‐therapy application

2004 • 74 citations

Rapid sulfopropyl-disk chromatographic purification of bovine and human thrombin

1986 • 73 citations

Properties of a Highly Punified Human Plasma Factor IX:c Therapeutic Concentrate Prepared by Conventional Chromatography

1989 • 71 citations

Mechanism of action of IVIG and anti-D in ITP

2003 • 70 citations

Role of von Willebrand factor in immune tolerance induction

2005 • 70 citations

A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period

2000 • 69 citations

A New Preparation of Modified Immune Serum Globulin (Human) Suitable for Intravenous Administration

1981 • 68 citations

Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy

2002 • 67 citations

Inactivation of Lipid‐Enveloped Viruses in Proteins by Caprylate

1991 • 59 citations

International Immune Tolerance Registry, 1997 Update

1999 • 59 citations

Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg

2004 • 59 citations

The economic impact of factor VIII inhibitors in patients with haemophilia

2004 • 57 citations

Factor concentrates for the treatment of factor XIII deficiency

1998 • 56 citations

New observations on factor XI deficiency

2004 • 55 citations

Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII:C inhibitors

1991 • 54 citations

Antibody-directed therapy: Past, present, and future☆☆☆

2001 • 54 citations

Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors

2007 • 54 citations

Activated prothrombin complex concentrate (FEIBA^®) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience

2004 • 53 citations

Current use of by‐passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors

2006 • 51 citations

Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin-1 receptor antagonist

2003 • 51 citations

The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high‐titre inhibitors: association of clinical outcome with inhibitor epitope profile

2007 • 50 citations

Serological analysis of patients treated with a new surgical hemostat containing bovine proteins and autologous plasma

2001 • 48 citations

Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products

2002 • 48 citations

Acquired haemophilia: experiences with a standardized approach

2001 • 47 citations

Fibrin sealant: clinical use and the development of the University of Virginia Tissue Adhesive Center.

2001 • 46 citations

Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1-3galactose.

2000 • 46 citations

Immunoadsorption may provide a cost‐effective approach to management of patients with inhibitors to FVIII

2003 • 46 citations

Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases.

1994 • 46 citations

Serological evidence that dry heating of clotting factor concentrates prevents transmission of non‐A, non‐B hepatitis

1990 • 45 citations

Ensuring the Biologic Safety of Plasma-Derived Therapeutic Proteins

2005 • 44 citations

In Hemophilia A and Autoantibody Inhibitor Patients: The Factor VIII A2 Domain and Light Chain Are Most Immunogenic

2001 • 44 citations

Virus Validation of PH 4-treated Human Immunoglobulin Produced by the Cohn Fractionation Process

1998 • 43 citations

Interferon immunogenicity: preclinical evaluation of interferon-alpha 2a.

1997 • 42 citations

Potential Contribution of Mild Pepsin Treatment at pH4 to the Viral Safety of Human Immunoglobulin Products

1988 • 42 citations

Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis

2001 • 41 citations

Intravenous Immune Globulins

1992 • 40 citations

Purification of Six Human Vitamin K-Dependent Proteins in a Single Chromatographic Step Using Immunoaffinity Columns¹

1986 • 40 citations

Anti‐D (WinRho SD^™) treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production

2002 • 38 citations

Evidence-Based Guidelines on the Use of Intravenous Immune Globulin for Hematologic and Neurologic Conditions

2007 • 37 citations

Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy

2006 • 37 citations

Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery

1999 • 36 citations

Severe Bleeding due to Factor V Inhibitor after Repeated Operations Using Fibrin Sealant Containing Bovine Thrombin

1997 • 35 citations

Massive Intravascular Hemolysis Associated with Intravenous Immunoglobulin in Bone Marrow Transplant Recipients

1988 • 35 citations

Serologic markers of viral hepatitis A, B, C, and D in patients with hemophilia

1993 • 35 citations

Comparisons of the Molecular Forms of Activated Bovine Factor X

1973 • 35 citations

A New Preparation of Modified Immune Serum Globulin (Human) Suitable for Intravenous Administration

1981 • 34 citations

Immunoadsorption of factor VIII inhibitors

2004 • 31 citations

IGIV in neurology--evidence and recommendations.

1999 • 31 citations

An overview of scientific and regulatory issues for the immunogenicity of biological products.

2003 • 30 citations

In vivo coagulation activation following infusion of highly purified factor XI concentrate

1997 • 30 citations

Hepatitis A Transmission by Factor IX Concentrates

1996 • 30 citations

A solvent/detergent‐treated and 15‐nm filtered factor VIII: a new safety standard for plasma‐derived coagulation factor concentrates

2007 • 29 citations

Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.

2007 • 29 citations

Fibrin glue in coronary artery bypass grafting operations: casting out the Devil with Beelzebub?

2007 • 28 citations

Relative Purity of Thrombin-Based Hemostatic Agents Used in Surgery

2003 • 25 citations

Clinical applications of intravenous immunoglobulin therapy

1993 • 25 citations

Clearance of Prions During Plasma Protein Manufacture

2005 • 22 citations

Opsonic activity of immunoglobulin prepared for intravenous use.

1984 • 22 citations

Ensuring the pathogen safety of intravenous immunoglobulin and other human plasma–derived therapeutic proteins☆☆☆

2001 • 21 citations

A Cross-over Pharmacokinetic Study of a Double Viral Inactivated Factor IX Concentrate (15 nm Filtration and SD) Compared to a SD Factor IX Concentrate

1998 • 20 citations

The Maintenance of Tolerance After Successful Immune Tolerance Induction in Hemophilia A and B: The North American Registry

2000 • 18 citations

Intravenous immunoglobulin (IVIG) preparations induce apoptosis in TNF-α-stimulated endothelial cells via a mitochondria-dependent pathway

2002 • 18 citations

Preparation and Properties of a Therapeutic Factor IX Concentrate

1977 • 17 citations

Platelet activation induced by porcine factor VIII (HYATE:C)

1998 • 17 citations

Autoantibodies to factor VIII

2002 • 16 citations

Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate

2005 • 15 citations

Effect of factor VIII concentrate on leucocyte cytokine receptor expression in vitro: relevance to inhibitor formation and tolerance induction

2006 • 15 citations

Intravenous Immunoglobulin Therapy for Acquired Coagulation Inhibitors: A Critical Review

2007 • 15 citations

Incidence of Factor IX Inhibitor Development in Severe Haemophilia B Patients Treated with only one Brand of High Purity Plasma Derived Factor IX Concentrate

1999 • 14 citations

Mapping of Natural Anti-Factor VIII Antibodies in Plasma Pools from Healthy Donors: Use of Rationally Designed Synthetic Peptides

2001 • 13 citations

Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates

2007 • 12 citations

Clinical Experience with a Pasteurised Human Plasma Concentrate in Factor XIII Deficiency

1988 • 12 citations

Factor IX replacement in surgery and prophylaxis

2004 • 10 citations

Successful induction of immune tolerance by continuous infusion of recombinant factor VIII in a haemophilia A patient with high‐inhibitor titres

2006 • 10 citations

Purification and Some Characteristics of the Human Coagulation Factor VII

1979 • 9 citations

Déficit en facteur XI, un nouveau moyen de substitution: les concentrés humains purifiés

1996 • 6 citations

Inhibitor development, immune tolerance and prophylaxis in haemophilia A – the need for an evidence‐based approach

2006 • 6 citations

MonoFIX‐VF, a new mono‐component factor IX concentrate: a single‐centre continuous‐infusion study

2002 • 5 citations

IVIg in the treatment of patients with factor VIII inhibitors

1995 • 1 citations

Anti idiotypic recognition of auto and allo antibodies to factor VIII by immunoglobulin preparations from single blood donors and large plasma pool.

1990 • 1 citations